Viral Technology Laboratory

弗雷德里克国家癌症研究所的病毒技术实验室（VTL）专注于致癌病毒发病机制以及病毒在癌症病因中的作用。使用成熟的技术以及尖端技术的组合，ESTA进行病毒学检测，是敏感的，具体的，具有成本效益和时间效率。ESTO还生产用于转基因或shRNA递送的定制慢病毒和腺病毒。这些病毒是强大的工具，使研究人员能够操纵和研究特定基因在癌症和各种其他疾病状态的病因学中的作用。ESTO提供用于基因表达的cDNA克隆，以及用于体外和体内基因递送和表达研究的重组慢病毒和腺病毒的设计、生成和纯化。此外，该公司还对各种标本类型（血液、细胞、血沉棕黄层、唾液、组织、肿瘤等）进行分子和血清学实验室检测。来检测和鉴定导致人类癌症的病毒。在过去的一年里，这个实验室经历了几次重大的变化。它以前是艾滋病疫苗计划（AVP）的病毒肿瘤科（VOS），但在2006年10月1日，该实验室转移到先进技术计划（ATP）。2007年4月1日，基因表达实验室（GEL）解散，GEL病毒生产组与VOS核心实验室合并。这增加了两名全职员工，以及慢病毒和腺病毒服务，因此，VOS核心更名为病毒技术实验室（Viral Technology Laboratory，简称VOS）。VOS与NCI研究人员合作，为所需的病毒学服务确定并提供最科学合理和最具成本效益的解决方案。该委员会由两个小组组成：血清学和分子检测组和病毒生产组，共同提供广泛的病毒学服务目录，以帮助研究人员推进他们的研究。血清学和分子检测集团该集团提供luminex多重细胞因子和细胞信号传导检测;使用内部和商业ELISA进行抗体检测和定量;经验证的定量实时PCR病毒检测（标准化为国际单位）;病毒和哺乳动物核酸的自动化高通量DNA和RNA提取，用于各种下游用途，包括PCR和SNP分析; DNA测序;开发用于全病毒基因组或细胞途径的定制表达阵列;以及使用这些阵列以及AFFYMETRIX人类基因阵列进行样品检测。癌症研究中心最初成立于1986年，作为病毒流行病学部门（VES），以支持NCI癌症流行病学和遗传学部门（NCI-DCEG）病毒流行病学分支（VEB）研究人员进行的大规模、基于人群的流行病学研究。

The Viral Technology Laboratory (VTL) at the National Cancer Institute - Frederick focuses on oncogenic viral pathogenesis and the role of viruses in cancer etiology. Using a combination of well-established techniques as well as cutting-edge technologies, VTL performs virological assays that are sensitive, specific, cost-effective, and time-efficient. VTL also produces custom lentiviruses and adenoviruses for transgene or shRNA delivery. These viruses are powerful tools that enable researchers to manipulate and study the role of specific genes in the etiology of cancer and various other disease states. VTL offers cDNA cloning for gene expression, as well as design, generation, and purification of recombinant lentiviruses and adenoviruses for gene delivery and expression studies in vitro and in vivo. VTL also performs molecular and serological laboratory testing on a variety of specimen types (blood, cells, buffy coat, saliva, tissues, tumors, etc.) to detect and characterize viruses that cause human cancers. During the past year, this laboratory has undergone several major changes. It was previously the Viral Oncology Section (VOS) of the AIDS Vaccine Program (AVP), but on October 1, 2006, the laboratory transferred to the Advanced Technology Program (ATP). As of April 1, 2007, the Gene Expression Laboratory (GEL) was disbanded and the GEL Virus Production Group merged with the VOS core laboratory. This added two full-time employees, as well as the lentiviral and adenoviral services, and as a result, VOS core was renamed the Viral Technology Laboratory (VTL).VTL collaborates with NCI investigators to determine and provide the most scientifically sound and costeffective solution for the requested virological service. VTL consists of two groups: the Serology and Molecular Assays Group and the Virus Production Group that together offer an extensive catalog of virology services to help investigators move their research forward. SEROLOGY AND MOLECULAR ASSAYS GROUP This VTL group offers luminex multiplex cytokine and cell signaling assays; antibody detection and quantification using in-house and commercial ELISAs; validated quantitative real-time PCR viral testing (standardized to International Units); automated highthroughput DNA and RNA extraction of viral and mammalian nucleic acids for various downstream uses, including PCR and SNP analysis; DNA sequencing; development of custom expression arrays for whole virus genomes or cellular pathways; and sample testing using these arrays as well as AFFYMETRIX human gene arrays. VTL was originally established in 1986 as the Viral Epidemiology Section (VES) to support large-scale, population-based epidemiological studies performed by investigators of the NCI Division of Cancer Epidemiology and Genetics (NCI-DCEG) Viral Epidemiology Branch (VEB).